Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 11, 2025
Deals

After stumbles along winding path, Acelyrin merges with Alumis: Deals Report

Plus: Pair of cash-rich biotechs agree to combine, and Australian radiopharma company Advancell follows venture round by expanding Lilly relationship
BioCentury | Dec 4, 2024
Product Development

Confidence in masked T cell engagers builds with Janux update

Also in BioCentury’s Clinical Report: Cartesian’s autoimmune CAR T durability, Roivant’s miss, Novocure’s pancreatic cancer data, and more
BioCentury | Nov 20, 2024
Discovery & Translation

Science Spotlight: A new obesity target may avoid nausea, muscle loss

BioCentury’s roundup of translational innovation: Embark/Novo discover new obesity target, Canbridge delivers large DMD gene, and more
BioCentury | Nov 20, 2024
Deals

Where the Ratio deal fits into Novartis’ radiopharma matrix

The deal grows Novartis’ ligand modality and chelator toolbox, and its focus on Lutathera target SSTR2
BioCentury | Oct 7, 2024
Distillery Therapeutics

Inhibiting Factor XII for diabetic kidney disease

BioCentury | May 28, 2024
Deals

J&J adds bispecific for atopic dermatitis via deal with Numab

Ten-figure M&A transaction with Swiss antibody company gives the pharma an immunology asset targeting IL-4RA and IL-31; builds on Proteologix deal
BioCentury | May 17, 2024
Product Development

Vectorized antibodies are taking gene therapy beyond rare disease

ASGCT presentations showcase cancers, infectious diseases and chronic inflammatory conditions as potential applications of vectorized antibodies
BioCentury | Apr 24, 2024
Product Development

Next-wave radiopharmaceuticals: insights from AACR

Fusion added to view of ɑ-emitters in lutetium-experienced patients, as Novartis, RayzeBio gave peeks at programs with broad indication potential
BioCentury | Mar 26, 2024
Distillery Therapeutics

Increasing podocyte NDUFS4 for diabetic kidney disease

BioCentury | Jan 26, 2024
Product Development

Growing IL-18 field looks to enhance cell therapies via decoy evasion

As more companies bring IL-18 into their cancer pipelines, they also bring new modalities and approaches to the cytokine’s inhibitory decoy receptor
Items per page:
1 - 10 of 826
Help Center
Username
Request a Demo
Request Training
Ask a Question